CompletedPhase 4

Study on the Influence of Electroconvulsive Therapy (ECT) on Homocysteine Levels

Germany10 participantsStarted 2006-08

Plain-language summary

Elevated homocysteine levels are associated with depression and cognitive impairment. When depression ameliorates due to treatment, homocysteine serum levels often normalize. Aim of the present study is to investigate, whether repeated ECT treatment leads to changes in homocysteine levels and if these changes are associated with the occurrence of cognitive impairment after ECS. 10 patients suffering from therapy-resistant depression shall be enrolled. Patients are treated with repeated ECT (three times the week). Before, directly after and one day after ECT treatment, blood samples are drawn and patients receive cognitive testing. Depressive symptomatology is checked with different rating scales.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * Men and women aged 18 years or above * Diagnosis of major depressive disorder (according to DSM IV) * Secured therapy resistance (at least two trials with antidepressive medication of different classes for more then 4 weeks in adequate dosage) * Written, informed consent Key Exclusion Criteria: * Major neurological or other diseases * Current medication with antiepileptic drugs * History of major head trauma * Any medical condition not allowing anesthesia

What they're measuring

Homocysteine serum levels

Trial details

NCT IDNCT00370058

SponsorUniversity of Erlangen-Nürnberg Medical School

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2007-08

View on ClinicalTrials.gov More Depressive Disorder, Major trials